Incyte (INCY) Stock Forecast, Price Target & Predictions
INCY Stock Forecast
Incyte stock forecast is as follows: an average price target of $84.56 (represents a 11.45% upside from INCY’s last price of $75.87) and a rating consensus of 'Buy', based on 21 wall street analysts offering a 1-year stock forecast.
INCY Price Target
The average price target for Incyte (INCY) is $84.56 based on 1-year price targets from 21 Wall Street analysts in the past 3 months, with a price target range of $200.00 to $48.00. This represents a potential 11.45% upside from INCY's last price of $75.87.
INCY Analyst Ratings
According to 21 Wall Street analysts, Incyte's rating consensus is 'Buy'. The analyst rating breakdown for INCY stock is 0 'Strong Buy' (0.00%), 14 'Buy' (66.67%), 7 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Incyte Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 30, 2024 | Aaron Kessler | Seaport Global | $200.00 | $73.00 | 173.97% | 163.61% |
| Oct 30, 2024 | Jay Olson | Oppenheimer | $82.00 | $73.60 | 11.41% | 8.08% |
| Oct 30, 2024 | David Lebowitz | Citigroup | $97.00 | $73.60 | 31.79% | 27.85% |
| Oct 29, 2024 | Kelly Shi | Jefferies | $84.00 | $73.60 | 14.13% | 10.72% |
| Oct 29, 2024 | Tazeen Ahmad | Bank of America Securities | $90.00 | $73.60 | 22.28% | 18.62% |
| Sep 30, 2024 | Andy Chen | Wolfe Research | $84.00 | $66.10 | 27.08% | 10.72% |
| Sep 16, 2024 | Tazeen Ahmad | Bank of America Securities | $68.00 | $63.56 | 6.99% | -10.37% |
| Sep 16, 2024 | Salveen Richter | Goldman Sachs | $60.00 | $63.56 | -5.60% | -20.92% |
| Aug 18, 2024 | David Lebowitz | Citigroup | $92.00 | $62.16 | 48.01% | 21.26% |
| Jul 31, 2024 | Brian Abrahams | RBC Capital | $66.00 | $65.70 | 0.46% | -13.01% |
The latest Incyte stock forecast, released on Oct 30, 2024 by Aaron Kessler from Seaport Global, set a price target of $200.00, which represents a 173.97% increase from the stock price at the time of the forecast ($73.00), and a 163.61% increase from INCY last price ($75.87).
Incyte Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 5 | 9 | 15 |
| Avg Price Target | $110.60 | $95.22 | $81.93 |
| Last Closing Price | $75.87 | $75.87 | $75.87 |
| Upside/Downside | 45.78% | 25.50% | 7.99% |
In the current month, the average price target of Incyte stock is $110.60, according to 5 Wall Street analysts offering twelve months forecast. The average price target represents a 45.78% increase as opposed to Incyte's last price of $75.87. This month's average price target is up 16.15% compared to last quarter, and up 34.99% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 30, 2024 | Seaport Global | - | Buy | Upgrade |
| Oct 30, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Oct 30, 2024 | BMO Capital | Underperform | Underperform | Hold |
| Oct 30, 2024 | Citigroup | Buy | Buy | Hold |
| Oct 29, 2024 | Jefferies | Buy | Buy | Hold |
| Oct 29, 2024 | Bank of America Securities | Neutral | Buy | Upgrade |
| Oct 23, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| Oct 22, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 01, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Oct 01, 2024 | Oppenheimer | Underperform | Underperform | Hold |
Incyte's last stock rating was published by Seaport Global on Oct 30, 2024. The company Upgrade its INCY rating from "null" to "Buy".
Incyte Financial Forecast
Incyte Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $919.02M | $954.61M | $808.67M | $926.70M | $823.30M | $911.40M | $733.24M | $862.85M | $812.99M | $705.71M | $604.72M | $789.51M | $620.64M | $688.04M | $568.51M | $579.39M | $551.58M |
| Avg Forecast | $1.38B | $1.36B | $1.28B | $1.11B | $1.26B | $1.19B | $1.14B | $1.00B | $1.14B | $1.08B | $1.01B | $921.89M | $1.00B | $963.63M | $909.68M | $859.17M | $878.25M | $842.66M | $818.49M | $749.98M | $812.44M | $746.09M | $685.41M | $659.08M | $660.12M | $622.63M | $608.32M | $556.06M | $575.04M | $534.94M |
| High Forecast | $1.44B | $1.41B | $1.33B | $1.16B | $1.31B | $1.24B | $1.19B | $1.03B | $1.18B | $1.08B | $1.01B | $921.89M | $1.04B | $999.01M | $948.75M | $896.06M | $915.97M | $842.66M | $818.49M | $749.98M | $812.44M | $746.09M | $685.41M | $659.08M | $660.12M | $622.63M | $608.32M | $556.06M | $575.04M | $534.94M |
| Low Forecast | $1.30B | $1.27B | $1.20B | $1.05B | $1.18B | $1.12B | $1.07B | $944.61M | $1.08B | $1.08B | $1.01B | $921.89M | $971.32M | $941.00M | $855.50M | $808.00M | $825.95M | $842.66M | $818.49M | $749.98M | $812.44M | $746.09M | $685.41M | $659.08M | $660.12M | $622.63M | $608.32M | $556.06M | $575.04M | $534.94M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 14 | 9 | 5 | 4 | 8 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 1.05% | 0.94% | 1.06% | 0.98% | 1.11% | 0.98% | 1.06% | 1.09% | 1.03% | 0.92% | 1.20% | 1.00% | 1.13% | 1.02% | 1.01% | 1.03% |
Incyte's average Quarter revenue forecast for Dec 23 based on 8 analysts is $1.00B, with a low forecast of $971.32M, and a high forecast of $1.04B. INCY's average Quarter revenue forecast represents a 9.11% increase compared to the company's last Quarter revenue of $919.02M (Sep 23).
Incyte EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 14 | 9 | 5 | 4 | 8 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $260.65M | $193.78M | $63.84M | $121.08M | $144.69M | $258.27M | $124.18M | $135.63M | $224.60M | $186.45M | $83.52M | $181.70M | $9.98M | $320.46M | $-690.38M | $139.96M | $162.48M |
| Avg Forecast | $218.41M | $214.11M | $201.69M | $175.76M | $198.44M | $187.49M | $180.13M | $158.48M | $180.21M | $170.36M | $160.34M | $125.06M | $158.42M | $152.25M | $143.72M | $113.69M | $283.01M | $130.38M | $126.64M | $103.35M | $125.70M | $115.44M | $106.05M | $79.60M | $102.13M | $96.33M | $94.12M | $-4.16B | $88.97M | $82.77M |
| High Forecast | $227.79M | $223.31M | $210.35M | $183.31M | $206.97M | $195.54M | $187.86M | $163.05M | $186.48M | $170.67M | $160.34M | $150.07M | $164.64M | $157.84M | $149.89M | $136.42M | $339.61M | $130.38M | $126.64M | $124.02M | $125.70M | $115.44M | $106.05M | $95.52M | $102.13M | $96.33M | $94.12M | $-3.32B | $88.97M | $82.77M |
| Low Forecast | $205.40M | $201.36M | $189.67M | $165.29M | $186.62M | $176.32M | $169.40M | $149.24M | $170.81M | $170.05M | $160.34M | $100.04M | $153.46M | $148.67M | $135.16M | $90.95M | $226.41M | $130.38M | $126.64M | $82.68M | $125.70M | $115.44M | $106.05M | $63.68M | $102.13M | $96.33M | $94.12M | $-4.99B | $88.97M | $82.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.71% | 1.35% | 0.56% | 0.43% | 1.11% | 2.04% | 1.20% | 1.08% | 1.95% | 1.76% | 1.05% | 1.78% | 0.10% | 3.40% | 0.17% | 1.57% | 1.96% |
8 analysts predict INCY's average Quarter EBITDA for Dec 23 to be $158.42M, with a high of $164.64M and a low of $153.46M. This is -39.22% lower than Incyte's previous annual EBITDA (Sep 23) of $260.65M.
Incyte Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 14 | 9 | 5 | 4 | 8 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $171.27M | $203.55M | $21.70M | $28.46M | $112.78M | $161.43M | $37.99M | $563.85M | $181.74M | $149.46M | $53.53M | $149.85M | $-15.20M | $290.30M | $-720.64M | $111.00M | $128.27M |
| Avg Forecast | $483.19M | $467.23M | $410.14M | $300.20M | $337.49M | $308.44M | $283.97M | $219.99M | $292.84M | $205.86M | $146.45M | $54.20M | $224.90M | $163.28M | $136.30M | $49.28M | $1.18B | $109.88M | $122.36M | $44.80M | $122.42M | $126.99M | $120.79M | $51.03M | $117.50M | $111.56M | $105.16M | $-4.34B | $77.61M | $96.77M |
| High Forecast | $510.17M | $493.31M | $433.04M | $316.96M | $356.34M | $325.66M | $299.82M | $241.81M | $370.42M | $217.35M | $154.63M | $65.04M | $249.06M | $193.70M | $143.91M | $59.13M | $1.41B | $109.88M | $122.36M | $53.76M | $122.42M | $126.99M | $120.79M | $61.23M | $117.50M | $111.56M | $105.16M | $-3.47B | $77.61M | $96.77M |
| Low Forecast | $445.78M | $431.06M | $378.39M | $276.96M | $311.36M | $284.56M | $261.98M | $185.45M | $124.12M | $189.92M | $135.11M | $43.36M | $202.60M | $100.85M | $125.75M | $39.42M | $941.23M | $109.88M | $122.36M | $35.84M | $122.42M | $126.99M | $120.79M | $40.82M | $117.50M | $111.56M | $105.16M | $-5.21B | $77.61M | $96.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.05% | 1.49% | 0.44% | 0.02% | 1.03% | 1.32% | 0.85% | 4.61% | 1.43% | 1.24% | 1.05% | 1.28% | -0.14% | 2.76% | 0.17% | 1.43% | 1.33% |
Incyte's average Quarter net income forecast for Dec 23 is $224.90M, with a range of $202.60M to $249.06M. INCY's average Quarter net income forecast represents a 31.32% increase compared to the company's last Quarter net income of $171.27M (Sep 23).
Incyte SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 14 | 9 | 5 | 4 | 8 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $267.89M | $283.93M | $315.61M | $272.82M | $266.50M | $253.28M | $209.58M | $226.20M | $190.70M | $168.90M | $153.80M | $167.00M | $120.80M | $118.00M | $113.28M | $136.18M | $102.61M |
| Avg Forecast | $350.59M | $343.70M | $323.75M | $282.13M | $318.55M | $300.96M | $289.15M | $254.39M | $289.28M | $273.47M | $257.38M | $299.04M | $254.30M | $244.39M | $230.71M | $271.85M | $471.99M | $213.71M | $207.58M | $247.14M | $206.05M | $189.22M | $173.83M | $146.59M | $167.41M | $157.91M | $154.28M | $141.02M | $145.84M | $135.67M |
| High Forecast | $365.65M | $358.46M | $337.66M | $294.25M | $332.23M | $313.89M | $301.56M | $261.73M | $299.34M | $273.96M | $257.38M | $358.85M | $264.28M | $253.36M | $240.61M | $326.23M | $566.39M | $213.71M | $207.58M | $296.57M | $206.05M | $189.22M | $173.83M | $175.91M | $167.41M | $157.91M | $154.28M | $141.02M | $145.84M | $135.67M |
| Low Forecast | $329.71M | $323.23M | $304.47M | $265.33M | $299.57M | $283.04M | $271.92M | $239.57M | $274.18M | $272.97M | $257.38M | $239.23M | $246.34M | $238.65M | $216.97M | $217.48M | $377.59M | $213.71M | $207.58M | $197.71M | $206.05M | $189.22M | $173.83M | $117.27M | $167.41M | $157.91M | $154.28M | $141.02M | $145.84M | $135.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.10% | 1.23% | 1.16% | 0.58% | 1.25% | 1.22% | 0.85% | 1.10% | 1.01% | 0.97% | 1.05% | 1.00% | 0.77% | 0.76% | 0.80% | 0.93% | 0.76% |
Incyte's average Quarter SG&A projection for Dec 23 is $254.30M, based on 8 Wall Street analysts, with a range of $246.34M to $264.28M. The forecast indicates a -5.07% fall compared to INCY last annual SG&A of $267.89M (Sep 23).
Incyte EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 14 | 9 | 5 | 4 | 8 | 14 | 13 | 7 | 6 | 6 | 8 | 6 | 7 | 11 | 7 | 13 | 13 | 15 | 9 | 9 | 16 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.76 | $0.91 | $0.10 | $0.13 | $0.51 | $0.73 | $0.17 | $2.55 | $0.82 | $0.68 | $0.24 | $0.68 | $-0.07 | $1.33 | $-3.33 | $0.51 | $0.60 |
| Avg Forecast | $2.47 | $2.39 | $2.09 | $1.53 | $1.72 | $1.57 | $1.45 | $1.12 | $1.50 | $1.05 | $0.75 | $0.78 | $1.15 | $0.83 | $0.70 | $0.56 | $0.30 | $0.50 | $0.56 | $0.46 | $0.56 | $0.58 | $0.55 | $0.45 | $0.54 | $0.51 | $0.48 | $0.35 | $0.36 | $0.44 |
| High Forecast | $2.61 | $2.52 | $2.21 | $1.62 | $1.82 | $1.66 | $1.53 | $1.23 | $1.89 | $1.11 | $0.79 | $0.79 | $1.27 | $0.99 | $0.73 | $0.59 | $0.32 | $0.50 | $0.56 | $0.46 | $0.56 | $0.58 | $0.55 | $0.45 | $0.54 | $0.51 | $0.48 | $0.35 | $0.36 | $0.44 |
| Low Forecast | $2.28 | $2.20 | $1.93 | $1.41 | $1.59 | $1.45 | $1.34 | $0.95 | $0.63 | $0.97 | $0.69 | $0.77 | $1.03 | $0.51 | $0.64 | $0.52 | $0.28 | $0.50 | $0.56 | $0.46 | $0.56 | $0.58 | $0.55 | $0.45 | $0.54 | $0.51 | $0.48 | $0.35 | $0.36 | $0.44 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 1.31% | 0.18% | 0.43% | 1.01% | 1.30% | 0.37% | 4.54% | 1.41% | 1.23% | 0.53% | 1.26% | -0.14% | 2.76% | -9.58% | 1.43% | 1.35% |
According to 8 Wall Street analysts, Incyte's projected average Quarter EPS for Dec 23 is $1.15, with a low estimate of $1.03 and a high estimate of $1.27. This represents a 51.11% increase compared to INCY previous annual EPS of $0.76 (Sep 23).
Incyte Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals | $26.27 | $74.50 | 183.59% | Buy |
| ARWR | Arrowhead Pharmaceuticals | $18.57 | $45.38 | 144.37% | Buy |
| RARE | Ultragenyx Pharmaceutical | $44.75 | $106.93 | 138.95% | Buy |
| SRPT | Sarepta Therapeutics | $104.54 | $169.06 | 61.72% | Buy |
| BMRN | BioMarin Pharmaceutical | $63.42 | $101.70 | 60.36% | Buy |
| DNLI | Denali Therapeutics | $25.05 | $40.00 | 59.68% | Buy |
| ACAD | ACADIA Pharmaceuticals | $16.77 | $26.57 | 58.44% | Buy |
| FOLD | Amicus Therapeutics | $9.68 | $15.25 | 57.54% | Buy |
| IONS | Ionis Pharmaceuticals | $34.34 | $51.68 | 50.50% | Buy |
| HRMY | Harmony Biosciences | $33.22 | $48.86 | 47.08% | Buy |
| BGNE | BeiGene | $189.23 | $255.80 | 35.18% | Buy |
| AXSM | Axsome Therapeutics | $93.17 | $122.42 | 31.39% | Buy |
| INCY | Incyte | $75.87 | $84.56 | 11.45% | Buy |
| ALNY | Alnylam Pharmaceuticals | $235.56 | $254.21 | 7.92% | Buy |
| UTHR | United Therapeutics | $363.25 | $358.20 | -1.39% | Buy |
| ARGX | argenx SE | $564.23 | $475.14 | -15.79% | Buy |
| RXDX | Prometheus Biosciences | $199.92 | $138.57 | -30.69% | Buy |